The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload

Sivgin, Serdar; Baldane, Süleyman; AKYOL, GÜLŞAH; Keklik, MUZAFFER; KAYNAR, LEYLAGÜL; Kurnaz, Fatih; Pala, Çiğdem; ZARARSIZ, GÖKMEN; ÇETİN, MUSTAFA; ESER, BÜLENT; Unal, ALİ

doi:10.1016/j.transci.2013.07.004

The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload

Atıf İçin Kopyala

Sivgin S., Baldane S., AKYOL G., Keklik M., KAYNAR L., Kurnaz F., ...Daha Fazla

TRANSFUSION AND APHERESIS SCIENCE, cilt.49, sa.2, ss.295-301, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 49 Sayı: 2
Basım Tarihi: 2013
Doi Numarası: 10.1016/j.transci.2013.07.004
Dergi Adı: TRANSFUSION AND APHERESIS SCIENCE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.295-301
Anahtar Kelimeler: Allogeneic haematopoietic stem cell, transplantation, Deferasirox, Iron overload, Survival, PRETRANSPLANTATION SERUM FERRITIN, MYELODYSPLASTIC SYNDROMES, MARROW-TRANSPLANTATION, THERAPY, ICL670, MORTALITY
Erciyes Üniversitesi Adresli: Evet

Özet

Introduction: Iron overload (10) has been shown to be an important cause of mortality and morbidity in patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). This study aimed to evaluate the possible effect of oral iron-chelation treatment (deferasirox) on survival in alloHSCT recipients in the posttransplant period.